{"id":"dosing-according-residual-heparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombosis (if underdosed)"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rather than a drug itself, this represents a clinical dosing strategy where heparin doses are individualized by measuring residual (remaining) heparin concentrations and adjusting subsequent doses accordingly. This approach aims to optimize anticoagulation efficacy while minimizing bleeding risk by maintaining heparin levels within a therapeutic window.","oneSentence":"This is a dosing protocol that adjusts heparin administration based on residual heparin levels in the patient's blood to maintain therapeutic anticoagulation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:33.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anticoagulation dosing optimization in patients requiring heparin therapy"}]},"trialDetails":[{"nctId":"NCT04628884","phase":"PHASE4","title":"Strategies for Protamine Dosing After Anticoagulation in Cardiovascular Surgery","status":"UNKNOWN","sponsor":"Fundación Clínica Shaio","startDate":"2020-11-15","conditions":"Anticoagulant Antagonist Toxicity","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dosing according residual heparin","genericName":"Dosing according residual heparin","companyName":"Fundación Clínica Shaio","companyId":"fundaci-n-cl-nica-shaio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a dosing protocol that adjusts heparin administration based on residual heparin levels in the patient's blood to maintain therapeutic anticoagulation. Used for Anticoagulation dosing optimization in patients requiring heparin therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}